Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
SAN DIEGO and TORONTO, April 03, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on Monday, April 9, 2018 at 11:30 a.m. CEST:
| Time: | 11:30 a.m. CEST | |||||
| Date: | Monday, April 9, 2018 | |||||
| Location: | Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco | |||||
| Live webcast: | http://wsw.com/webcast/hcw2/apto/ |
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |
